Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.
- Authors
- Morikawa, Y; Arai, H; Matsushita, S; Kato, M; Higuchi, S; Miura, M; Kawakami, H; Higuchi, M; Okamura, N; Tashiro, M; Matsui, T; Sasaki, H
- Year
- 1999
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 10235290
- DOI
- 10.1111/j.1530-0277.1999.tb04156.x
The tau protein levels in cerebrospinal fluid (CSF-tau) were examined in 27 patients with alcohol dependence (20 demented and 7 nondemented), 36 age and dementia severity-matched patients with Alzheimer's disease (AD), and 23 age-matched normal control subjects. The CSF-tau levels in the demented alcoholic group (alcohol-induced organic brain disorders, 25.4 +/- 10.2 pg/ml) was significantly lower (p < 0.0001) than that in the AD group (96.1 +/- 53.3 pg/ml), but not significantly different from that in the nondemented alcoholics (18.1 +/- 10.2 pg/ml) or the controls (19.2 +/- 12.9 pg/ml). Using a 44.9 pg/ml as a cut-off value (mean + 2 SD of the normal control group), only one patient with alcohol-induced organic brain disorders exceeded the value, whereas 3 of 36 of the AD group showed CSF-tau levels less than this level. These findings suggest that alcohol-induced organic brain disorders are a group of dementias that are characterized by normal CSF-tau levels, and that the CSF examination for tau in combination with other clinical findings may help in differentiating alcohol-induced organic brain disorders from AD.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. | 2021 | 34417470 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Cerebrospinal Fluid Biomarkers in Patients With Alcohol Use Disorder and Persistent Cognitive Impairment. | Azuar J et al. | β | 2021 | β |
| Multi-omics integration analysis identifies novel genes for alcoholism with potential overlap with neurodegenerative diseases. | Kapoor M et al. | β | 2021 | β |
| Emerging biomarkers in cognition. | Wicklund M et al. | β | 2013 | β |
| Cerebrospinal fluid and blood biomarkers in Alzheimer's disease. | Humpel C et al. | β | 2011 | β |
| An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. | Petzold A et al. | β | 2010 | β |
| CSF Biomarkers for Alzheimer's Disease Diagnosis. | Anoop A et al. | β | 2010 | β |
| Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. | Palmio J et al. | β | 2009 | β |
| The neuropathology of alcohol-related brain damage. | Harper C | β | 2009 | β |
| Alcohol enhances Abeta42-induced neuronal cell death through mitochondrial dysfunction. | Lee DY et al. | β | 2008 | β |
| Elevated cerebrospinal fluid tau protein levels in Wernicke's encephalopathy. | Matsushita S et al. | β | 2008 | β |
| Neuropathology of alcohol-related cognitive alterations. | Harper C et al. | β | 2008 | β |
| The neurotoxicity of alcohol. | Harper C | β | 2007 | β |
| Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. | Formichi P et al. | β | 2006 | β |
| Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. | Blasko I et al. | β | 2006 | β |
| Cognitive impairment and diffuse white matter atrophy in alcoholics. | Mochizuki H et al. | β | 2005 | β |
| CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. | Andreasen N et al. | β | 2005 | β |
| The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages. | Kapaki E et al. | β | 2005 | β |
| Cerebrospinal fluid protein biomarkers for Alzheimer's disease. | Blennow K | β | 2004 | β |
| CSF biomarkers for mild cognitive impairment. | Blennow K | β | 2004 | β |
| CSF tau and Ξ²-amyloid as biomarkers for mild cognitive impairment. | Hampel H et al. | β | 2004 | β |
| Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. | SjΓΆgren M et al. | β | 2003 | β |
| Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. | Hampel H et al. | β | 2003 | β |
| CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. | Andreasen N et al. | β | 2003 | β |
| CSF markers for incipient Alzheimer's disease. | Blennow K et al. | β | 2003 | β |
| CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. | Blennow K et al. | β | 2003 | β |
| Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. | Teunissen CE et al. | β | 2002 | β |
| Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. | Vanmechelen E et al. | β | 2001 | β |
| CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. | Blennow K et al. | β | 2001 | β |
| No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome. | Matsushita S et al. | β | 2001 | β |
| Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. | Blennow K et al. | β | 2000 | β |
| Proteomics in molecular medicine: applications in central nervous systems disorders. | Rohlff C | β | 2000 | β |